Cost of Revenue of ACCENDRA HEALTH INC/VA/ from 30 Jun 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
ACCENDRA HEALTH INC/VA/ quarterly and annual Cost of Revenue in USD history and change rate from 30 Jun 2010 to 31 Dec 2025.
  • ACCENDRA HEALTH INC/VA/ Cost of Revenue for the quarter ending 31 Dec 2025 was $1,365,684,000, a 0.81% increase year-over-year.
  • ACCENDRA HEALTH INC/VA/ Cost of Revenue for the twelve months ending 31 Dec 2025 was $1,472,733,000, a 5.2% increase year-over-year.
  • ACCENDRA HEALTH INC/VA/ annual Cost of Revenue for 2025 was $1,472,733,000, a 5.2% increase from 2024.
  • ACCENDRA HEALTH INC/VA/ annual Cost of Revenue for 2024 was $1,399,732,000, a 4.8% increase from 2023.
  • ACCENDRA HEALTH INC/VA/ annual Cost of Revenue for 2023 was $1,335,552,000, a 84% decline from 2022.
Source SEC data
View on sec.gov
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Change (%)
Cost of Revenue, Annual (USD)
Cost of Revenue, YoY Annual Change (%)

ACCENDRA HEALTH INC/VA/ Quarterly Cost of Revenue (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $1,472,733,000 $1,365,684,000 +$11,182,000 +0.81% 01 Oct 2025 31 Dec 2025 10-K 20 Feb 2026 2025 FY
Q3 2025 $1,461,551,000 $375,067,000 +$19,992,000 +5.6% 01 Jul 2025 30 Sep 2025 10-Q 31 Oct 2025 2025 Q3
Q2 2025 $1,441,559,000 $357,315,000 +$12,943,000 +3.8% 01 Apr 2025 30 Jun 2025 10-Q 11 Aug 2025 2025 Q2
Q1 2025 $1,428,616,000 $2,106,035,000 +$28,884,000 +1.4% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $1,399,732,000 $1,376,866,000 +$3,410,162,000 +71% 01 Oct 2024 31 Dec 2024 10-K 20 Feb 2026 2025 FY
Q3 2024 $2,010,430,000 $355,075,000 -$1,698,169,000 -83% 01 Jul 2024 30 Sep 2024 10-Q 31 Oct 2025 2025 Q3
Q2 2024 $312,261,000 $344,372,000 -$1,699,422,000 -83% 01 Apr 2024 30 Jun 2024 10-Q 11 Aug 2025 2025 Q2
Q1 2024 $1,387,161,000 $2,077,151,000 +$51,609,000 +2.5% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $1,335,552,000 $4,787,028,000 -$6,931,016,000 -323% 01 Oct 2023 31 Dec 2023 10-K 20 Feb 2026 2025 FY
Q3 2023 $8,266,568,000 $2,053,244,000 +$69,122,000 +3.5% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024 2024 Q3
Q2 2023 $8,197,446,000 $2,043,794,000 +$76,284,000 +3.9% 01 Apr 2023 30 Jun 2023 10-Q 02 Aug 2024 2024 Q2
Q1 2023 $8,121,162,000 $2,025,542,000 -$7,962,000 -0.39% 01 Jan 2023 31 Mar 2023 10-Q 03 May 2024 2024 Q1
Q4 2022 $8,129,124,000 $2,143,988,000 +$18,413,000 +0.87% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2025 2024 FY
Q3 2022 $8,110,711,000 $1,984,122,000 -$189,214,000 -8.7% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $8,299,925,000 $1,967,510,000 -$121,882,000 -5.8% 01 Apr 2022 30 Jun 2022 10-Q 04 Aug 2023 2023 Q2
Q1 2022 $8,421,807,000 $2,033,504,000 +$149,721,000 +7.9% 01 Jan 2022 31 Mar 2022 10-Q 05 May 2023 2023 Q1
Q4 2021 $8,272,086,000 $2,125,575,000 +$162,267,000 +8.3% 01 Oct 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
Q3 2021 $8,109,819,000 $2,173,336,000 +$329,747,000 +18% 01 Jul 2021 30 Sep 2021 10-Q 02 Nov 2022 2022 Q3
Q2 2021 $7,780,072,000 $2,089,392,000 +$551,080,000 +36% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 $7,228,992,000 $1,883,783,000 +$29,649,000 +1.6% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $7,199,343,000 $1,963,308,000 +$57,396,000 +3% 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $7,141,947,000 $1,843,589,000 -$168,541,000 -8.4% 01 Jul 2020 30 Sep 2020 10-Q 03 Nov 2021 2021 Q3
Q2 2020 $7,310,488,000 $1,538,312,000 -$551,875,000 -26% 01 Apr 2020 30 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 $7,862,363,000 $1,854,134,000 -$220,085,000 -11% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q4 2019 $8,082,448,000 $1,905,912,000 -$148,282,000 -7.2% 01 Oct 2019 31 Dec 2019 10-K 23 Feb 2022 2021 FY
Q3 2019 $8,230,730,000 $2,012,130,000 -$100,173,000 -4.7% 01 Jul 2019 30 Sep 2019 10-Q 03 Nov 2020 2020 Q3
Q2 2019 $8,330,903,000 $2,090,187,000 -$43,090,000 -2% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $8,373,993,000 $2,074,219,000 +$26,327,000 +1.3% 01 Jan 2019 31 Mar 2019 10-Q 06 May 2020 2020 Q1
Q4 2018 $8,347,666,000 $2,054,194,000 01 Oct 2018 31 Dec 2018 10-K 04 Mar 2020 2019 FY
Q3 2018 $2,112,303,000 +$80,284,000 +4% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $2,133,277,000 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $2,047,892,000 01 Jan 2018 31 Mar 2018 10-Q 07 May 2019 2019 Q1
Q3 2017 $2,032,019,000 01 Jul 2017 30 Sep 2017 10-Q 05 Nov 2018 2018 Q3
Q3 2010 $1,866,157,000 01 Jul 2010 30 Sep 2010 10-Q 29 Oct 2010 2010 Q3
Q2 2010 $1,827,674,000 01 Apr 2010 30 Jun 2010 10-Q 30 Jul 2010 2010 Q2

ACCENDRA HEALTH INC/VA/ Annual Cost of Revenue (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $1,472,733,000 +$73,001,000 +5.2% 01 Jan 2025 31 Dec 2025 10-K 20 Feb 2026 2025 FY
2024 $1,399,732,000 +$64,180,000 +4.8% 01 Jan 2024 31 Dec 2024 10-K 20 Feb 2026 2025 FY
2023 $1,335,552,000 -$6,793,572,000 -84% 01 Jan 2023 31 Dec 2023 10-K 20 Feb 2026 2025 FY
2022 $8,129,124,000 -$142,962,000 -1.7% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2025 2024 FY
2021 $8,272,086,000 +$1,072,743,000 +15% 01 Jan 2021 31 Dec 2021 10-K 20 Feb 2024 2023 FY
2020 $7,199,343,000 -$883,105,000 -11% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $8,082,448,000 -$265,218,000 -3.2% 01 Jan 2019 31 Dec 2019 10-K 23 Feb 2022 2021 FY
2018 $8,347,666,000 +$201,257,000 +2.5% 01 Jan 2018 31 Dec 2018 10-K 04 Mar 2020 2019 FY
2017 $8,146,409,000 -$389,712,000 -4.6% 01 Jan 2017 31 Dec 2017 10-K 06 Mar 2019 2018 FY
2016 $8,536,121,000 01 Jan 2016 31 Dec 2016 10-K 06 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.